KET NO.: WYNC-0330/AM101206(NP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Dahui Zhou and Gary Paul Stack

Confirmation No.: 3756

Application No.: 10/659,167

Group Art Unit: 1614

Filing Date: September 10, 2003

Examiner: Not yet known

Antidepressant Azaheterocyclymethyl Derivatives of Heterocycle-Fused

Benzodioxans

DATE OF DEPOSIT: March 4, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED NAME: Heather Kite

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

¥. . .

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is \boxtimes being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

	the above identified	application as set forth in § 1.491, before the mailing date						
	of a first Office Action on the merits of the above-identified application before the mailing date of a first Office Action after the filing of requestion continued examination under § 1.114, no additional fee is required.							
	In accordance with	§ 1.97(c), this Information Disclosure Statement is being						
	filed after the period set forth in § 1.97(b) above but before the mailing d							
	either a Final Action under § 1.113 or a Notice of Allowance under § 1.311							
before an action that otherwise closes prosecution in the application,								
		Certification in Accordance with § 1.97(e) is attached;						
		or						
		The fee of $$180.00$ as set forth in § 1.17(p) is attached.						
	In accordance with	§ 1.97(d), this Information Disclosure Statement is being						
	filed after the mailin	g date of either a Final Action under § 1.113 or a Notice						
	of Allowance under § 1.311 but before, or simultaneously with, the payme							
	of the Issue Fee, therefore included are: Certification in Accordance v							
	1.97(e); and the subr	nission fee of \$180.00 as set forth in § 1.17(p).						
\boxtimes	Copies of each of the	ne references listed on the attached Form PTO-1449 are						
	enclosed herewith.							
	Copies of reference	s listed on the attached Form PTO-1449 are enclosed						
	herewith EXCEPT T	HAT:						
	Copies of references	listed on the attached Form PTO 1449 are not required to						
	be submitted pursua	ant to the June 30, 2003 recent revisions to 37 CFR §						
	1.98(a)(2)(i).							

DOCKET NO.: WYNC-0330/AM101206(NP) - 3 -

PATENT

EXCEPT THAT:

In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C.§ 120 have been made in the instant application:

Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No.

, filed

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Enclosed is a copy of the corresponding PCT/US03/28413 Search Report dated February 10, 2004.

There are no listed references which are not in the English language.

Date: March 4, 2004

Wendy A. Choil

Registration No. 36,697

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439



orm PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Docket No.
WYNC-0330/
AM101206(NP)

Application No. 10/659,167

Applicant

Dahui Zhou and Gary Paul Stack

Filing Date September 10, 2003 Group 1614

Confirmation No. 3756

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
	24	2002/0183355 A1	12/05/02	Tran et al.	514	302

FOREIGN PATENT DOCUMENTS

				Translation	
	Document No.	Date	Country	YES	NO
25	0 559 285 A1	09/08/93	EP		
26	0 771 800 A2	05/07/97	EP		
27	0 963 983 A1	12/15/99	EP		
28	02/072587 A1	09/19/02	wo		
29	02/085911 A1	10/31/02	wo		
	26 27 28	25 0 559 285 A1 26 0 771 800 A2 27 0 963 983 A1 28 02/072587 A1	25 0 559 285 A1 09/08/93 26 0 771 800 A2 05/07/97 27 0 963 983 A1 12/15/99 28 02/072587 A1 09/19/02	25 0 559 285 A1 09/08/93 EP 26 0 771 800 A2 05/07/97 EP 27 0 963 983 A1 12/15/99 EP 28 02/072587 A1 09/19/02 WO	Document No. Date Country YES 25 0 559 285 A1 09/08/93 EP EP 26 0 771 800 A2 05/07/97 EP EP 27 0 963 983 A1 12/15/99 EP EP 28 02/072587 A1 09/19/02 WO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Birch, A. M. et al., "N-Substituted (2,3-Dihydro-1,4-benzodioxin-2-yl)methylamine Derivatives as D₂ Antagonists/5-HT_{1A} Partial Agonists with Potential as Atypical Antipsychotic Agents," *J Med Chem*, **1999**, 42, 3342-3355

EXAMINER

DATE CONSIDERED